Iowanews Headlines

New York, USA – December 30, 2025 – Ace Therapeutics announces the enhancement of its liver fibrosis CRO services with disease model customization that will empower researchers globally to further mechanistic studies of liver disease and drive drug discovery. Aiming to replicate the intricate pathophysiology of liver fibrosis, Ace Therapeutics’ custom models serve the specific requirements of academic and pharmaceutical research groups by enabling the translation between animal modelling in early development and clinical validation.

Innovative In Vitro Models: Recreating Liver Physiology on Cellular and Tissue Scales

Ace Therapeutics’ portfolio of in vitro liver fibrosis models is designed to be physiologically relevant, providing a number of tools to mimic the complexity of human liver tissue and progression of disease from early-stage fibrosis through regenerative repair.

* Primary Hepatic Stellate Cells (HSCs): Available in multiple activation states, enabling precise studies of HSC-driven pathogenesis—the core of liver fibrosis.

* HSC Cell Lines: Including the widely used LX-2 cell line, optimized for genetic manipulation and high-throughput drug screening, accelerating candidate validation.

* iPSC-Derived HSCs: Custom-developed induced pluripotent stem cell (iPSC)-derived HSCs that closely mimic primary cells, providing a scalable, ethically sound alternative for mechanistic research and long-term drug studies.

* Co-Culture Systems: Tailored co-cultures of HSCs with hepatocytes, bile duct endothelial cells, Kupffer cells (KCs), and other liver resident cells, simulating critical cell-cell interactions and the tissue microenvironment that drive fibrosis progression.

Customized Liver Fibrosis Models: Recapitulating Clinical Heterogeneity

Ace Therapeutics’ animal models span multiple species and induction methods, ensuring alignment with diverse research goals:

* Chemically Induced Models: Available in rats, mice, macaques, and marmosets, using established toxins such as carbon tetrachloride (CCl4), thioacetamide (TAA), nitrosamines (DMN, DEN), arsenic, acetaminophen (APAP), and D-galactosamine (D-GalN), as well as alcohol-induced protocols.

* Diet-Induced Models: Tailored for Ossabaw pigs, mice, and rats, including choline-deficient diet (MCD), high-fat diet (HFD), Western diet (WD), CDAA, and CDAHFD-induced models—critical for studying NASH-related fibrosis.

* Surgical Models: Bile duct ligation (BDL) in rats and mice, replicating biliary fibrosis.

* Immune Induction Models: Rat and mouse models induced by Schistosoma infection, viruses, porcine serum (PS), or Concanavalin A, addressing immune-mediated liver fibrosis.

* Combined Induction Models: Innovative combinations of chemicals (e.g., CCl4 + ethanol), chemicals + diets (e.g., HFD + ethanol, CCl4 + WD), and transgenic + diets (e.g., ob/ob + HFD) to mimic complex clinical scenarios.

Ace Therapeutics’ customization approach ensures that each model is tailored to specific research objectives—from target validation and pathway analysis to efficacy evaluation of drug candidates. By leveraging physiologically relevant models, researchers can reduce translational risk and accelerate the development of novel therapies for liver fibrosis.

About Ace Therapeutics

Ace Therapeutics specializes in the development of sophisticated preclinical models for gastrointestinal and hepatological diseases. With a focus on customization, quality, and scientific rigor, the company supports academic institutions, biotech firms, and pharmaceutical companies worldwide in advancing research and accelerating drug development. Ace Therapeutics’ portfolio of models addresses unmet needs in disease areas including liver fibrosis, NASH, hepatitis, and gastrointestinal disorders, enabling breakthroughs in translational medicine.

Media Contact
Company Name: Ace Therapeutics
Contact Person: Daisy Mostert
Email: Send Email
Phone: 1-516-441-0167
Country: United States
Website: https://www.acetherapeutics.com/gi-and-hepatology